CSIMarket
 
Beam Therapeutics Inc   (BEAM)
Other Ticker:  
 
 
Price: $29.8100 $-0.51 -1.682%
Day's High: $30.97 Week Perf: 17.09 %
Day's Low: $ 29.21 30 Day Perf: 20.06 %
Volume (M): 1,349 52 Wk High: $ 49.50
Volume (M$): $ 40,226 52 Wk Avg: $26.39
Open: $29.89 52 Wk Low: $16.95



 Market Capitalization (Millions $) 2,356
 Shares Outstanding (Millions) 79
 Employees -
 Revenues (TTM) (Millions $) 82
 Net Income (TTM) (Millions $) -314
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 38

Beam Therapeutics Inc


   Company Address: 238 Main Street Cambridge 2142 MA
   Company Phone Number: 327-8775   Stock Exchange / Ticker: NASDAQ BEAM
   


Customers recorded net loss Customers recorded net loss



• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FBIN   -5.7%    
MAS        1.86% 
MO        1.19% 
NWL   -2.42%    
SEB        1.23% 
SWK        0.33% 
• View Complete Report
   



Clinical Study

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency ...

Published Wed, Jun 26 2024 10:30 AM UTC

Beam Therapeutics' Groundbreaking BEAM-302 Enters Clinical Trial for Alpha-1 Antitrypsin Deficiency, While Suppliers Face Financial ChallengesConclusion:Beam Therapeutics Inc.'s dosing of the first patient with BEAM-302 in the Phase 1/2 clinical trial for severe alpha-1 antitrypsin deficiency represents a significant advancement in precision genetic medicines. The therapy's ...

Clinical Study

Beam Therapeutics Optimized Manufacturing Process Boosts Sickle Cell Disease Therapy Development

Published Fri, Jun 14 2024 7:00 AM UTC

Beam Therapeutics, a leading biotechnology company specializing in precision genetic medicines through base editing, has announced significant progress in the manufacturing process for BEAM-101, an investigational base editing therapeutic for sickle cell disease (SCD). The company presented data at the European Hematology Association (EHA) Hybrid Congress, highlighting the s...

Product Service News

In the ever-evolving realm of biotechnology, Beam Therapeutics Inc., a trailblazer in the field of base editing technology, is poised to present a significant stride in its operational capabilities at the highly anticipated 2024 European Hematology Association (EHA) Hybrid Congress. The company is set to unveil the advancements of BEAM-101, a beacon of hope in the treatment of hema...

Published Tue, May 14 2024 8:00 PM UTC

'Beam Therapeutics Triumphs in Manufacturing, Faces Financial Turbulence: A Close Look Ahead of the 2024 EHA Hybrid Congress'In the ever-evolving realm of biotechnology, Beam Therapeutics Inc., a trailblazer in the field of base editing technology, is poised to present a significant stride in its operational capabilities at the highly anticipated 2024 European Hematology Ass...

Product Service News

Beam Therapeutics: A Beacon of Hope for AATD Treatment With Revenue Growth Amidst Strong Competition

Published Tue, Mar 26 2024 10:30 AM UTC

Beam Therapeutics Announces Clearance of Clinical Trial Authorization Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Beam Therapeutics, a leading biotechnology company, has recently announced the clearance of its clinical trial authorization application for BEAM-302, a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD). This mil...

Beam Therapeutics Inc

Beam Therapeutics Inc Reports Disturbing $-1.22 Per Share Deficit During July-September 2023 Financial Period


Date:
Beam Therapeutics Inc, a leading company in the Biotechnology & Pharmaceuticals sector, has emerged as a beacon of hope amidst a challenging market environment. The company's financial performance for the July to September 30, 2023 financial interval demonstrates its ability to overcome obstacles and navigate through unprecedented circumstances.
During this period, Beam reported a loss of $-1.22 per share, marking an improvement from the $-1.56 loss per share recorded in the previous year. Additionally, the company's revenue for the quarter experienced significant growth, advancing by 8.823% to $17.19 million, compared to $15.80 million in the corresponding reporting season a year prior.






 

Beam Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com